All In Biotech

Drug Trial Radar · NCT06345729

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

May 24, 2024

Primary completion

Jan 24, 2028

Study completion Feb 18, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There is one primary study hypothesis: Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • CalderasibDrug

    Oral tablets

  • PlaceboOther

    Oral tablets

  • PembrolizumabBiological

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 42 months

Locations

248 sites in 30 countries. Site status is shown where the registry gives one.

  • CBCC Global Research, Inc. ( Site 0123)

    Bakersfield, California · Recruiting

  • Beverly Hills Cancer Center ( Site 0116)

    Beverly Hills, California · Recruiting

  • Stamford Hospital ( Site 0136)

    Stamford, Connecticut · Recruiting

  • Mount Sinai Cancer Center ( Site 0137)

    Miami Beach, Florida · Completed

  • Orchard Healthcare Research Inc. ( Site 0115)

    Skokie, Illinois · Recruiting

  • Truman Medical Center ( Site 0126)

    Kansas City, Missouri · Recruiting

  • Cox Medical Center North ( Site 0133)

    Springfield, Missouri · Recruiting

  • St. Vincent Frontier Cancer Center-Research ( Site 0105)

    Billings, Montana · Recruiting

  • Atlantic Health System Morristown Medical Center ( Site 0121)

    Morristown, New Jersey · Completed

  • New York Oncology Hematology, P.C. ( Site 0132)

    Albany, New York · Recruiting

  • University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103)

    Cincinnati, Ohio · Recruiting

  • Kettering Health Main Campus-Kettering Health Cancer Center ( Site 0106)

    Kettering, Ohio · Completed

  • Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134)

    Lancaster, Pennsylvania · Recruiting

  • Oncology Consultants P.A. ( Site 0113)

    Houston, Texas · Recruiting

  • Circuit Clinical/SSM Health Dean Medical Group ( Site 0129)

    Madison, Wisconsin · Recruiting

  • Centro de Oncología e Investigación de Buenos Aires ( Site 0308)

    Berazategui, Buenos Aires, Argentina · Recruiting

  • AUSTRAL MEDICAL CENTER ( Site 0302)

    CABA, Buenos Aires, Argentina · Completed

  • Centro Oncologico Korben ( Site 0304)

    CABA, Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0300)

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Clinica Viedma S. A ( Site 0307)

    Viedma, Río Negro Province, Argentina · Recruiting

  • Fundacion Estudios Clinicos ( Site 0306)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Sanatorio Parque ( Site 0301)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Chris O'Brien Lifehouse ( Site 3000)

    Camperdown, New South Wales, Australia · Recruiting

  • Cancer Care Service Hervey Bay ( Site 3003)

    Urraween, Queensland, Australia · Recruiting

  • Frankston Hospital ( Site 3002)

    Frankston, Victoria, Australia · Recruiting

  • One Clinical Research ( Site 3001)

    Nedlands, Western Australia, Australia · Recruiting

  • Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2400)

    Vienna, Austria · Recruiting

  • Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 2401)

    Graz, Styria, Austria · Recruiting

  • Instituto Nacional de Câncer - INCA ( Site 0446)

    Rio de Janeiro, Brazil · Recruiting

  • Americas ( Site 0431)

    Rio de Janeiro, Brazil · Recruiting

  • Hospital Mario Penna ( Site 0436)

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Hospital de Câncer de Recife ( Site 0447)

    Recife, Pernambuco, Brazil · Recruiting

  • Oncoclínica Oncologistas Associados ( Site 0441)

    Teresina, Piauí, Brazil · Completed

  • Liga Norte Riograndense Contra o Câncer ( Site 0439)

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Hospital de Caridade de Ijuí ( Site 0438)

    Ijuí, Rio Grande do Sul, Brazil · Recruiting

  • Hospital de Clínicas de Passo Fundo ( Site 0442)

    Passo Fundo, Rio Grande do Sul, Brazil · Recruiting

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre-Centro Multidisciplinar de Pesquisa Clínica ( Site 0435)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0437)

    Barretos, São Paulo, Brazil · Recruiting

  • MHAT - Heart and Brain ( Site 1006)

    Pleven, Bulgaria · Recruiting

  • Medical Center Futuremeds ( Site 1007)

    Plovdiv, Bulgaria · Recruiting

Showing 40 of 248 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.